Mesenchymal stem cells in systemic sclerosis therapy

Area of Science:

• Immunology
• Regenerative Medicine
• Autoimmune Diseases

Background:

• Systemic sclerosis (SSc) is a rare, heterogeneous autoimmune disorder with high mortality and no cure.
• Current understanding of SSc pathophysiology remains incomplete, driving the search for novel treatments.
• Cellular therapy, particularly using mesenchymal stem cells (MSCs), presents a promising avenue for SSc management.

Purpose of the Study:

• To explore the potential of mesenchymal stem cells (MSCs) in managing systemic sclerosis (SSc).
• To review the current evidence and ongoing research regarding MSCs-based therapy for SSc.
• To highlight the need for rigorous verification of MSCs' effectiveness and safety in SSc.

Main Methods:

• Review of preclinical studies using animal models of SSc.
• Analysis of clinical trial data involving autologous and allogeneic MSCs from various sources.
• Assessment of MSCs' attributes relevant to SSc pathophysiology.

Main Results:

• Preclinical trials in animal models have provided valuable insights into SSc.
• Clinical trials have tested MSCs from diverse sources, indicating feasibility.
• MSCs possess attributes relevant to key aspects of SSc.

Conclusions:

• Mesenchymal stem cells (MSCs) offer significant therapeutic potential for systemic sclerosis (SSc).
• Further rigorous evaluation of MSCs' efficacy and safety is essential.
• Optimizing MSCs-based therapies, potentially in combination with other treatments, requires further investigation.